

Aviso de Derechos para emisoras del

FECHA: 28/11/2025



BOLSA MEXICANA DE VALORES, S.A.B DE C.V, INFORMA:

FOLIO DE REFERENCIA DEL EVENTO CORPORATIVO	272724
FOLIO DE REFERENCIA INDEVAL	859753C004
TIPO DE MENSAJE	Replace
COMPLETO / INCOMPLETO	COMPLETE
CONFIRMADO / NO CONFIRMADO	CONFIRMED

CLAVE DE COTIZACIÓN	CVAC
RAZÓN SOCIAL	CUREVAC N.V.
SERIE	N
ISIN	NL0015436031
MERCADO PRINCIPAL	NASDAQ

TIPO DE EVENTO	EXCHANGE
----------------	----------

MANDATORIO / OPCIONAL / VOLUNTARIO	Voluntary
------------------------------------	-----------

OPCIÓN	999
TIPO	NoAction
DEFAULT	true

NOTA	
TAKE NO ACTION	

OPCIÓN	1
TIPO	Security
DEFAULT	false

Aviso de Derechos para emisoras del

FECHA: 28/11/2025

TRANSACCIÓN	Securities Movement
CREDIT / DEBIT	Debit

VALORES A RECIBIR	NL0015436031

TRANSACCIÓN	Securities Movement
CREDIT / DEBIT	Credit

RATIO	NewToOld
	0.05363 / 1
VALORES A RECIBIR	US09075V1026
DISPOSICIÓN FRACCIONES	CashInLieuOfFraction

NOTA
Holders who exchange their CureVac shares will receive a number of BioNTech ADSs (American Depositary Shares) at a rate to be determined for each share surrendered.

NOTAS DEL EVENTO CORPORATIVO

NOTA
(28/11/2025) US SEC CA 0206 425 Filed by BioNTech SE Exhibit 99.1 BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025 at 9.00 a.m. Eastern Time Expiration Offer set to expire at 9.00 am Eastern Time on December 3, 2025, with CureVacshareholders advised to tender their shares by 6.00 pm Eastern Time on December 2, 2025, due to operational deadlines. Exchange ratio of 0.05363 of a BioNTech American Depositary Share (ADS) for each CureVacshare, determined based on the volume-weighted average price of BioNTech ADSs over the 10 trading days ending November 25, 2025. CureVac shareholders approved matters relatedto BioNTech s exchange offer at their extraordinary general meeting held on November 25, 2025. MAINZ, Germany, November 26, 2025 BioNTech SE (Nasdaq. BNTX, BioNTech) today announced the approval of matters relating to the exchange offer (the Offer) for all outstanding shares of CureVac N.V. (Nasdaq. CVAC, CureVac) at the extraordinary general meeting (EGM) held by CureVac on November 25, 2025. At the EGM, over99.16PCT of votes cast by CureVac shareholders were in favor of the proposals relating to the Offer. BioNTech expects to complete the pending Offer as soon as reasonably practicable. CureVac shareholders are advised to tender their shares by 6.00 p.m. Eastern Time on Tuesday, December 2, 2025, to ensure processingbefore the scheduled expiration time of 9.00 a.m. Eastern Time on Wednesday, December 3, 2025. Althoughthe Offer technically expires at 9.00 a.m. Eastern Time on December 3,2025, operational deadlines at theDepository Trust Company and the exchange agent require shares to betendered by 6.00 p.m. Eastern Timeon December 2, 2025. No guaranteeddelivery procedures apply. Assumingthat the Offer expires at 9.00 a.m. Eastern Time on December 3, 2025,the exchange ratio (the Exchange Ratio) is 0.05363 of a BioNTech ADSper CureVac share. This calculation of the Exchange Ratio is based onthe volume weighted average priceof a BioNTech ADS as reported on Nasdaq for each of the 10 consecutivetrading days ending on, and including, November 25, 2025, or USD101.88. If the Offer is extended, BioNTech will recalculate the Exchange Ratio based on the later expected final expiration time and announce thenew exchange ratio by issuing a press release. Shareholders of CureVac who hold shares through a brokerage firm, bank or other nominee should tender their shares by providinginstructions to their broker, bankor other nominee. Other CureVac shareholders may tender their sharesby following the instructions provided in the Letter of Transmittal circulated on October 21, 2025. CureVac shareholders who have questionsor requests for assistance should contact Georgeson LLC, the Information Agent for the Offer, by phone at+1 (888) 686.7195 (toll free) or +1 (732) 353.1948 (collect), or viaemail at Curevacoffer

Aviso de Derechos para emisoras del



FECHA: 28/11/2025

georgeson.com. Following the time of acceptance for exchange of tendered CureVac shares by BioNTech in connection with the Offer, BioNTech will provide a subsequent offering period in accordance with Rule 14d.11 promulgated under the Securities Exchange Act of 1934 (as amended, the Exchange Act), of not less than 10 business days (calculated in accordance with Rule 14d.1(g)(3) under the Exchange Act) (the Subsequent Offering Period). The Offer is conditioned upon receipt by BioNTech of a number of CureVac shares having been validly tendered and not properly withdrawn that would allow BioNTech to acquire at least 80 PCT of the issued and outstanding CureVac shares at the closing of the Offer (the Minimum Condition). If all of the Offer conditions have been met besides the Minimum Condition, and BioNTech has extended the Offer on four or more occasions, BioNTech may elect to reduce the Minimum Condition to 75 PCT of the issued and outstanding CureVac shares, in which case the Offer shall be extended for at least ten business days.

US SEC CA 0031 SCHEDULE 14D.9 CureVac N.V. (Name of Subject Company) This Amendment No. 3 (this Amendment) to Schedule 14D.9 amends and supplements the Schedule 14D.9 previously filed by CureVac N.V., a public limited liability company (naamloze vennootschap) organized under the laws of the Netherlands having its registered office (statutaire zetel) in Amsterdam, the Netherlands, registered with the Dutch trade register under number 77798031 (the Company or CureVac) on October 21, 2025 with the U.S. Securities and Exchange Commission (the SEC) (as amended or supplemented from time to time, the Schedule 14D.9), with respect to the exchange offer (the Offer) by BioNTech SE, a European stock corporation (Societas Europaea) organized under the laws of Germany and the European Union, registered with the commercial register at the district court of Mainz under HRB 48720 (Buyer or BioNTech), and the Tender Offer Statement on Schedule TO, filed by Buyer with the SEC on October 21, 2025 (together with the exhibits thereto, as may be amended from time to time, the Schedule TO), pursuant to which Buyer is offering to exchange each ordinary share, par value EURO 0.12 per share, of the Company validly tendered and not properly withdrawn pursuant to the Offer for the right to receive (such consideration, the Offer Consideration) a number of American Depositary Shares of BioNTech (BioNTech ADSs), each representing one BioNTech ordinary share. Capitalized terms used in this Amendment but not defined herein shall have the respective meaning given to such terms in the Schedule 14D.9

US OCC Date. November 13, 2025 Subject. CureVac N.V. Exchange Offer Option Symbol. CVAC Date. 12 03 2025 CureVac N.V. (CVAC) is the subject of an Offer to Exchange, as described below. Purchaser. BioNTech SE (BNTX) Security to be Purchased. CureVac N.V. (CVAC) Ordinary Shares Quantity. All CureVac N.V. (CVAC) Ordinary Shares Offer Terms. A number of BioNTech SE (BNTX) American Depositary Shares based on an exchange ratio, calculated as described in the CVAC Offer to Exchange Prospectus dated October 21, 2025 (the Offer). Cash will be paid in lieu of fractional BNTX shares, if any. The number of BNTX ADSs paid to shares tendered in the Exchange Offer will be referred to as the Offer Consideration. Note. The exchange ratio is expected to be between 0.04318 and 0.06476 BNTX shares per CVAC share held. Expiration. 9.00 A.M., New York City time, on December 3, 2025, unless extended Depositary. Computershare Trust Company, N.A. Guaranty Period. None

US SEC CA 0196 425 1 d42810d425.htm BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V. Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next milestone in the execution of its oncology strategy. CureVac shareholders receive approximately USD 5.46 in BioNTech American Depositary Shares for each CureVac share, subject to a collar. An indicative exchange ratio will be available at www.envisionreports.com. CureVac Offer for the duration of the exchange offer. Information on how CureVac shareholders can participate in the exchange offer is available via Georgeson LLC, the information agent for the exchange offer, at +1 888 686 7195 (toll free in the US), +1 732 353 1948 (collect), or CureVacoffer.georgeson.com. Exchange offer will expire at 9.00 a.m. (New York City time) on December 3, 2025, unless extended or terminated earlier, in accordance with the terms of the Purchase Agreement MAINZ, Germany, October 22, 2025 (GLOBE NEWSWIRE). BioNTech SE (Nasdaq: BNTX, BioNTech) today announced it had commenced its public exchange offer (the Offer) for all outstanding shares of CureVac N.V. (Nasdaq: CVAC, CureVac). The Offer is being made pursuant to the previously announced purchase agreement between BioNTech and CureVac, dated as of June 12, 2025 (the Purchase Agree

26/11/2025

US SEC CA 0031 SCHEDULE 14D.9 CureVac N.V. (Name of Subject Company) This Amendment No. 3 (this Amendment) to Schedule 14D.9 amends and supplements the Schedule 14D.9 previously filed by CureVac N.V., a public limited liability company (naamloze vennootschap) organized under the laws of the Netherlands having its registered office (statutaire zetel) in Amsterdam, the Netherlands, registered with the Dutch trade register under number 77798031 (the Company or CureVac) on October 21, 2025 with the U.S. Securities and Exchange Commission (the SEC) (as amended or supplemented from time to time, the Schedule 14D.9), with respect to the exchange offer (the Offer) by BioNTech SE, a European stock corporation (Societas Europaea) organized under the laws of Germany and the European Union, registered with the commercial register at the district court of Mainz under HRB 48720 (Buyer or BioNTech), and the Tender Offer Statement on Schedule TO, filed by Buyer with the SEC on October 21, 2025 (together with the exhibits thereto, as may be amended from time to time, the Schedule TO), pursuant to which Buyer is offering to exchange each ordinary share, par value EURO 0.12 per share, of the Company validly tendered and not properly withdrawn pursuant to the Offer for the right to receive (such consideration, the Offer Consideration) a number of American Depositary Shares of BioNTech (BioNTech ADSs), each representing one BioNTech ordinary share. Capitalized terms used in this Amendment but not defined herein shall have the respective meaning given to such terms in the Schedule 14D.9

14/11/2025

US OCC Date. November 13, 2025 Subject. CureVac N.V. Exchange Offer Option Symbol. CVAC Date. 12 03 2025 CureVac N.V. (CVAC) is the subject of an Offer to Exchange, as described below. Purchaser. BioNTech SE (BNTX) Security to be Purchased. CureVac N.V. (CVAC) Ordinary Shares Quantity. All CureVac N.V. (CVAC) Ordinary Shares Offer Terms. A number of BioNTech SE (BNTX) American Depositary Shares based on an exchange ratio, calculated as described in the CVAC Offer to Exchange Prospectus dated October 21, 2025 (the Offer). Cash will be paid in lieu of fractional BNTX shares, if any. The number of BNTX ADSs paid to shares tendered in the

Aviso de Derechos para emisoras del



FECHA: 28/11/2025

Exchange Offer will be referred to as the Offer Consideration. Note. The exchange ratio is expected to be between 0.04318 and 0.06476 BNTX shares per CVAC share held. Expiration. 9.00 A.M., New York City time, on December 3, 2025, unless extended. Depositary. Computershare Trust Company, N.A. Guaranty Period. None (As on 22 10 2025) US SEC CA 0196 425 1d42810d425.htm. BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V. Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next milestone in the execution of its oncology strategy. CureVac shareholders receive approximately USD5.46 in BioNTech American Depositary Shares for each CureVac share, subject to a collar. An indicative exchange ratio will be available at www.envisionreports.com/CureVacOffer for the duration of the exchange offer. Information on how CureVac shareholders can participate in the exchange offer is available via Georgeson LLC, the information agent for the exchange offer, at +1 888 686 7195 (toll free in the US), +1 732 353 1948 (collect), or Curevacoffer@georgeson.com. Exchange offer will expire at 9.00 a.m. (New York City time) on December 3, 2025, unless extended or terminated earlier, in accordance with the terms of the Purchase Agreement MAINZ, Germany, October 22, 2025 (GLOBE NEWSWIRE). BioNTech SE (Nasdaq: BNTX, BioNTech) today announced it had commenced its public exchange offer (the Offer) for all outstanding shares of CureVac N.V. (Nasdaq: CVAC, CureVac). The Offer is being made pursuant to the previously announced purchase agreement between BioNTech and CureVac, dated as of June 12, 2025 (the Purchase Agreement). Upon closing, the transaction will bring together two pioneers in mRNA science with complementary capabilities and technologies to advance the development of innovative and transformative investigational mRNA-based cancer immunotherapies for patients in need. With the acquisition, BioNTech aims to strengthen its research, development, manufacturing, and commercialization capabilities, complementing its expertise in mRNA design, delivery formulations, and mRNA manufacturing. The transaction marks a milestone in the execution of BioNTech's oncology strategy, which focuses on two pan-tumor programs: mRNA-based cancer immunotherapy candidates, and pumitamicig (BNT327), a PD.L1xVEGF.A bispecific antibody candidate. BioNTech's all-stock acquisition of CureVac is expected to create long-term value for shareholders of both companies, building on BioNTech's proven track record in mRNA research, development, manufacturing, and commercialization. Under the terms of the Purchase Agreement, each CureVac share will be exchanged for approximately USD5.46 in BioNTech American Depositary Shares (ADSs), resulting in an implied aggregate equity value for CureVac of approximately USD1.25 billion (subject to the adjustments described below). The consideration is subject to a collar mechanism, such that if the 10-day volume weighted average price of a BioNTech ADS ending on, and including, the fifth business day prior to the closing of the Offer (VWAP) is greater than or equal to USD126.55, each CureVac share will be exchanged (the Exchange Ratio) for 0.04318 of a BioNTech ADS, and if the VWAP is less than or equal to USD84.37, the Exchange Ratio will be 0.06476 of a BioNTech ADS. For the duration of the Offer, an indicative Exchange Ratio will be available at www.envisionreports.com/CureVacOffer. CureVac shareholders who want to participate in the Offer should contact their broker, dealer, or other nominee through which they hold their CureVac shares for further information. Any CureVac shareholder who has any questions, including regarding how to participate, may reach out to the information agent for the Offer, Georgeson LLC, at +1 888 686 7195 (toll free in the US), +1 732 353 1948 (collect) or Curevacoffer@georgeson.com. 24/10/2025

BioNTech and CureVac have agreed (subject to the terms and conditions of the Purchase Agreement) that BioNTech will commence an offer to exchange any and all of the outstanding CureVac shares for the offer consideration, without interest and subject to applicable tax withholding.

Following the acceptance time, BioNTech will acquire each CureVac share validly tendered and not properly withdrawn prior to the expiration time by delivery of the offer consideration, with cash paid in lieu of any fractional ADSs, without interest and subject to applicable tax withholding, which we refer to as the closing of the offer.

As promptly as practicable following the expiration of the subsequent offering period, BioNTech and CureVac will effectuate the post-offer reorganization. The post-offer reorganization will utilize processes available to BioNTech under Dutch law aimed at ensuring that, if the required resolutions are adopted at the EGM (or subsequent EGM) and if permitted under applicable law, BioNTech becomes the sole owner of all of CureVac's business operations from and after the consummation of such post-offer reorganization. Following completion of, and effective one day following, the post-offer reorganization, BioNTech will cause New Topco to make the New Topco U.S. tax election.

In addition to a number of shares having been validly tendered and not properly withdrawn that would allow BioNTech to acquire at least 80% of CureVac's issued and outstanding capital immediately prior to the expiration time (or 75% of CureVac's issued and outstanding capital, upon the satisfaction of certain conditions described elsewhere in this offer to exchange/prospectus) there are a number of customary conditions that must be satisfied or waived before BioNTech is obligated to acquire CureVac shares validly tendered and not properly withdrawn pursuant to the offer.

In the offer, CureVac shareholders will have the right to exchange each of their CureVac shares for a number of BioNTech ADSs equal to the amount obtained by dividing USD 5.4641 by the volume-weighted average of the price per BioNTech ADS over the period of 10 consecutive trading days ending on, and including, the fifth trading day immediately preceding the expiration time. In the event the BioNTech ADS VWAP is greater than or equal to USD 126.55, the exchange ratio will be 0.04318 and, in the event, the BioNTech ADS VWAP is less than or equal to USD 84.37, the exchange ratio will be 0.06476.

From June 12, 2025, when BioNTech and CureVac announced the execution of the Purchase Agreement, through October 20, 2025 (the last practicable date before the commencement of the offer), the BioNTech ADS VWAP was not greater than or equal to USD 126.55 or less than or equal to USD 84.37. Accordingly, the offer consideration at all times during that period represented a market value of USD 5.4641. However, as shown below, were the BioNTech ADS VWAP to, for example, drop to USD 80 or go above USD 130 on the applicable calculation date, the market value of the offer consideration could be greater than or less than, respectively, USD 5.4641. Accordingly, as of the date of this offer to exchange/prospectus, CureVac shareholders will not know, or be able to calculate, the exact market value of the consideration that they will receive upon closing of the offer or completion of the post-offer reorganization.

BioNTech will only deliver whole BioNTech ADSs in the offer. To the extent a CureVac shareholder otherwise would be entitled to a

Aviso de Derechos para emisoras del



FECHA: 28/11/2025

fractional BioNTech ADS as a result of the application of the exchange ratio, such shareholder will instead receive an amount in cash equal to the product of (i) the fractional BioNTech ADS interest such shareholder otherwise would be entitled to and (ii) the BioNTech ADS VWAP.

If you are the record owner of your CureVac shares and you tender your shares directly through Computershare Trust Company, N.A., which we refer to as the exchange agent, you will not have to pay brokerage fees, commissions, or similar expenses. If you own CureVac shares through a broker, dealer, commercial bank, trust company, or other nominee and your broker, dealer, commercial bank, trust company, or other nominee tenders your CureVac shares on your behalf, your broker, dealer, commercial bank, trust company, or nominee may charge you a fee for doing so. You should consult your broker, dealer, commercial bank, trust company, or nominee to determine whether any charges will apply.

How will untendered CureVac shares be affected after the offer?

If all conditions are satisfied or waived (including, if applicable, the reduced minimum condition of 75%) and the offer expires then, as promptly as practicable following the expiration of the subsequent offering period, BioNTech and CureVac will effectuate the post-offer reorganization and the New Topco U.S. tax election. See The Offer The Post-Offer Reorganization and the New Topco U.S. Tax Election beginning on page 59.

As a result of the post-offer reorganization, CureVac will cease to exist and no public shareholders will continue to hold shares in it. Any holders of CureVac shares who do not participate in the offer, including the subsequent offering period, will receive the same consideration in the post-offer reorganization as such holder would have received had it participated in the offer. However, BioNTech ADSs (and cash in lieu of fractional BioNTech ADSs) received pursuant to the post-offer reorganization will, in principle, be subject to Dutch dividend withholding tax at a rate of 15% if and to the extent the cancellation consideration exceeds the average paid-in capital as recognized for Dutch dividend withholding tax purposes, which we refer to as the fiscally recognized capital, of the New Topco A shares immediately prior to the cancellation effective time, whereas no Dutch dividend withholding tax is applicable to the offer consideration received in exchange for the CureVac shares tendered in the offer or during the subsequent offering period.

Notwithstanding the above, as long as New Topco has its place of effective management in Germany and is therefore exclusively considered a tax resident of Germany under the 2012 Convention between the Federal Republic of Germany and the Kingdom of the Netherlands for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with respect to Taxes on Income, which we refer to as the double tax treaty between Germany and the Netherlands, as currently expected, the Netherlands will be restricted from imposing Dutch dividend withholding tax in respect of the cancellation consideration, except in the event the cancellation consideration is paid to (i) a shareholder who is resident or deemed to be resident in the Netherlands for Dutch income tax purposes or Dutch corporate income tax purposes, which we refer to as a Dutch resident holder, or (ii) a shareholder who is not resident nor deemed to be resident in the Netherlands for Dutch income tax purposes or Dutch corporate income tax purposes but who derives profits from an enterprise which enterprise is carried on, in whole or in part, through a permanent establishment or a permanent representative in the Netherlands, to which its New Topco A shares are attributable, which we refer to as a Dutch PE holder.

In order to apply this regime correctly, New Topco needs to identify its shareholders to assess whether they are Dutch resident holders and/or Dutch PE holders. As a practical matter, New Topco will not be able to make this confirmation with certainty prior to the cancellation effective time. Therefore, by default, Dutch dividend withholding tax will be withheld on the cancellation consideration if and to the extent the cancellation consideration exceeds the fiscally recognized capital of the New Topco A shares immediately prior to the cancellation effective time.

BioNTech intends to complete the offer as soon as reasonably practicable following satisfaction of all of the required conditions. It is currently expected that the offer will be completed in 2025. However, there is no guarantee that the conditions to the offer will be satisfied or waived or that the offer will close.

BioNTech currently expects to deliver BioNTech ADSs for CureVac shares tendered (i) in the offer approximately 10 business days from the expiration time and (ii) in the subsequent offering period approximately 10 business days from the expiration of the subsequent offering period.

Neither CureVac's shareholders nor New Topco's shareholders are entitled under Dutch law to exercise appraisal rights in connection with the offer or the post-offer reorganization.

The offer expires at 9:00 a.m. (New York City time) on December 3, 2025, unless the offer is extended or terminated in accordance with the Purchase Agreement.

Following the acceptance time, BioNTech will provide a subsequent offering period in accordance with Rule 14d-11 promulgated under the Exchange Act of not less than 10 business days (calculated in accordance with Rule 14d-1(g)(3) under the Exchange Act).

A CureVac shareholder may properly withdraw CureVac shares tendered pursuant to the offer at any time prior to the expiration time.

CureVac shares tendered during the subsequent offering period may not be withdrawn.

Contact information for the information agent (Georgeson LLC) is: Call Collect (732) 353-1948 Call Toll-Free (888) 686-7195 Email: Curevacoffer@georgeson.com.

During the offer, an indicative exchange ratio (calculated in the manner described in the offer to exchange/prospectus) will be available at www.envisionreports.com/CureVacOffer, beginning on October 22, 2025.

Aviso de Derechos para emisoras del



FECHA: 28/11/2025

Holders are reminded that the DTC cutoff time for all instructions and protects (if applicable) for this offer is 6pm ET, the business day prior to the actual expiration date. DTC is not able to accept nor facilitate instructions or protects (if applicable) after the stated DTC cutoff time.

Holders are further advised that although the offer's cutoff time (9:00 a.m. (New York City time) on December 3, 2025), is after DTC's processor's cutoff time, the Agent (Computershare) has informed DTC that they will not accept any instruction or tender (or protects, if applicable) from any DTC Participant outside of DTC, including during the period between 6pm and offer's cutoff time.

No Dutch withholding tax is applicable to the offer consideration received in exchange for CureVac shares tendered in the offer, including during any subsequent offering period.

However, BioNTech ADSs (and cash in lieu of fractional BioNTech ADSs) received pursuant to the mandatory event will be subject to Dutch withholding tax at a rate of 15%.

There is no Notice of Guaranteed of Delivery (protect) privilege afforded this offer.

US SEC CA 0196 425 1 d42810d425.htm BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V. Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech's next milestone in the execution of its oncology strategy. CureVac shareholders receive approximately USD5.46 in BioNTech American Depositary Shares for each CureVac share, subject to a collar. An indicative exchange ratio will be available at www.envisionreports.com/CureVacOffer for the duration of the exchange offer. Information on how CureVac shareholders can participate in the exchange offer is available via Georgeson LLC, the information agent for the exchange offer, at +1 888 686 7195 (toll free in the US), +1 732 353 1948 (collect), or CureVacoffer@georgeson.com. Exchange offer will expire at 9.00 a.m. (New York City time) on December 3, 2025, unless extended or terminated earlier, in accordance with the terms of the Purchase Agreement. MAINZ, Germany, October 22, 2025 (GLOBENEWSWIRE) BioNTech SE (Nasdaq: BNTX, BioNTech) today announced it had commenced its public exchange offer (the Offer) for all outstanding shares of CureVac N.V. (Nasdaq: CVAC, CureVac). The Offer is being made pursuant to the previously announced purchase agreement between BioNTech and CureVac, dated as of June 12, 2025 (the Purchase Agreement). Upon closing, the transaction will bring together two pioneers in mRNA science with complementary capabilities and technologies to advance the development of innovative and transformative investigational mRNA-based cancer immunotherapies for patients in need. With the acquisition, BioNTech aims to strengthen its research, development, manufacturing, and commercialization capabilities, complementing its expertise in mRNA design, delivery formulations, and mRNA manufacturing. The transaction marks a milestone in the execution of BioNTech's oncology strategy, which focuses on two pan-tumor programs: mRNA-based cancer immunotherapy candidates, and pumitumab (BNT327), a PD-L1xVEGF-A bispecific antibody candidate. BioNTech's all-stock acquisition of CureVac is expected to create long-term value for shareholders of both companies, building on BioNTech's proven track record in mRNA research, development, manufacturing, and commercialization. Under the terms of the Purchase Agreement, each CureVac share will be exchanged for approximately USD5.46 in BioNTech American Depositary Shares (ADSs), resulting in an implied aggregate equity value for CureVac of approximately USD1.25 billion (subject to the adjustments described below). The consideration is subject to a collar mechanism, such that if the 10-day volume weighted average price of a BioNTech ADS ending on, and including, the fifth business day prior to the closing of the Offer (VWAP) is greater than or equal to USD126.55, each CureVac share will be exchanged (the Exchange Ratio) for 0.04318 of a BioNTech ADS, and if the VWAP is less than or equal to USD84.37, the Exchange Ratio will be 0.06476 of a BioNTech ADS. For the duration of the Offer, an indicative Exchange Ratio will be available at www.envisionreports.com/CureVacOffer. CureVac shareholders who want to participate in the Offer should contact their broker, dealer, or other nominee through which they hold their CureVac shares for further information. Any CureVac shareholder who has any questions, including regarding how to participate, may reach out to the information agent for the Offer, Georgeson LLC, at +1 888 686 7195 (toll free in the US), +1 732 353 1948 (collect) or CureVacoffer@georgeson.com. (As on 21 10 2025) US SEC 0102 CureVac N.V. FORM F.4 Amendment No. 2 BIONTECH SE THE OFFER AND THE WITHDRAWAL RIGHTS WILL EXPIRE AT 9.00 A.M. (NEW YORK CITY TIME) ON DECEMBER 3, 2025, UNLESS THE OFFER IS EXTENDED OR TERMINATED IN ACCORDANCE WITH THE PURCHASE AGREEMENT. The supervisory board and management board, which we refer to together as the BioNTech boards, of BioNTech SE, European stock corporation (Societas Europaea, or SE) organized under the laws of Germany and the European Union, which we refer to as BioNTech, have unanimously approved a Purchase Agreement, dated as of June 12, 2025, which we refer to as the Purchase Agreement, by and between BioNTech and CureVac N.V., a public limited liability company (naamloze vennootschap) incorporated under the laws of the Netherlands, which we refer to as CureVac. Pursuant to the Purchase Agreement, BioNTech will commence an exchange offer, which we refer to as the offer, to acquire all of the outstanding ordinary shares, par value Eur0.12 per share, of CureVac, which we refer to as the CureVac shares. In exchange for each CureVac share, the tendering CureVac shareholder will receive a number of American Depositary Shares, taken to five decimal places, each representing one ordinary share, no par value, with a notional amount attributable to each ordinary share of Eur1, of BioNTech, which we refer to as BioNTech ADSs, equal to the amount obtained by dividing USD5.4641 by the volume-weighted average of the price per BioNTech ADS, taken to four decimal places, over the period of 10 consecutive trading days ending on, and including, the fifth trading day immediately preceding the expiration time (as defined below), which we refer to as the BioNTech ADS VWAP. We refer to the ratio of BioNTech ADSs to be received per CureVac share tendered pursuant to the foregoing as the exchange ratio and the BioNTech ADS received per CureVac share as the offer consideration. In the event the BioNTech ADS VWAP is greater than or equal to USD126.55, the exchange ratio will be 0.04318 and in the event the BioNTech ADS VWAP is less than or equal to USD84.37, the exchange ratio will be 0.06476. The exchange ratio will be fixed following the close of trading on Nasdaq on the fifth trading day prior to the scheduled expiration time. BioNTech will announce the number of BioNTech ADSs to be exchanged for each CureVac share by issuing a press release no later than 9.00 a.m. (New York City time) on the fourth trading day prior to the then-scheduled expiration time. If the offer is extended, BioNTech will recalculate this information based on the later expected final expiration time and announce the new exchange ratio in a similar manner. During the offer, an indicative exchange ratio (calculated in the manner described in this offer to exchange prospectus) will be available at www.envisionreports.com/CureVacOffer, beginning on October 22, 2025. The offer will initially remain open until 9.00 a.m. (New York City time) on December 3, 2025, unless the offer is extended or terminated in accordance with the Purchase Agreement. We refer to the time at which the offer expires as the expiration time. Following the time of acceptance for exchange of tendered CureVac shares by BioNTech in connection with the offer, which we refer to as the

Aviso de Derechos para emisoras del

FECHA: 28/11/2025



acceptance time, BioNTech will provide a subsequent offering period in accordance with Rule 14d.11 promulgated under the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act, of not less than 10 business days (calculated in accordance with Rule 14d.1(g)(3) under the Exchange Act), which we refer to as the subsequent offering period. (As on 11 08 2025) US SECCA 0056 FORM F.4 BIONTECH SE THE OFFER The following is a description of the material aspects of the offer. While BioNTech believes that the following description covers the material terms of the offer, the description may not contain all of the information that is important to CureVac shareholders. BioNTech encourages CureVac shareholders to carefully read this entire offer to exchange prospectus, including the Purchase Agreement and the other documents attached to this offer to exchange prospectus and incorporated herein by reference, for a more complete understanding of the offer. Offer Consideration Purs